Samrat Pharmachem Limited (BOM:530125)
India
· Delayed Price · Currency is INR 211.50
+1.55 (0.74%)
At close: Apr 28, 2026
Samrat Pharmachem Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 2,892 | 2,859 | 2,816 | 3,106 | 2,218 | 1,790 | Upgrade
|
| Other Revenue | 0.68 | 0.68 | 0.57 | 0.99 | 1.07 | 1.49 | Upgrade
|
| Revenue | 2,892 | 2,859 | 2,816 | 3,107 | 2,219 | 1,792 | Upgrade
|
| Revenue Growth (YoY) | -2.75% | 1.52% | -9.37% | 40.06% | 23.83% | 30.28% | Upgrade
|
| Cost of Revenue | 2,811 | 2,667 | 2,703 | 2,779 | 1,899 | 1,642 | Upgrade
|
| Gross Profit | 81.14 | 191.83 | 113.21 | 328.8 | 319.58 | 149.22 | Upgrade
|
| Selling, General & Admin | 25.57 | 25.35 | 23.62 | 20.51 | 18.37 | 15.77 | Upgrade
|
| Other Operating Expenses | 61.58 | 62.39 | 64.46 | 67.99 | 57.48 | 40.73 | Upgrade
|
| Operating Expenses | 94.1 | 94.28 | 94.55 | 94.94 | 81.8 | 63.7 | Upgrade
|
| Operating Income | -12.96 | 97.54 | 18.66 | 233.86 | 237.78 | 85.52 | Upgrade
|
| Interest Expense | -8.53 | -4.86 | -5.53 | -9.3 | -3.64 | -9.37 | Upgrade
|
| Interest & Investment Income | 3.69 | 3.69 | 3.05 | 2 | 1.38 | 0.86 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.6 | 0.6 | 0.32 | 1.53 | 0.6 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.61 | -1.21 | -1.35 | -3.02 | -0.18 | -3.4 | Upgrade
|
| EBT Excluding Unusual Items | -17.82 | 95.76 | 15.15 | 225.07 | 235.94 | 73.6 | Upgrade
|
| Gain (Loss) on Sale of Investments | 4.05 | 4.05 | 9.87 | 0.23 | 0.08 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.95 | -0.95 | 0.18 | - | -0.23 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -0.18 | Upgrade
|
| Pretax Income | -14.71 | 98.86 | 25.2 | 225.3 | 236.01 | 73.44 | Upgrade
|
| Income Tax Expense | 2.04 | 27.74 | 3.58 | 59 | 64.16 | 20.11 | Upgrade
|
| Net Income | -16.75 | 71.12 | 21.63 | 166.31 | 171.85 | 53.33 | Upgrade
|
| Net Income to Common | -16.75 | 71.12 | 21.63 | 166.31 | 171.85 | 53.33 | Upgrade
|
| Net Income Growth | - | 228.87% | -87.00% | -3.23% | 222.22% | 25.88% | Upgrade
|
| Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade
|
| EPS (Basic) | -5.42 | 23.02 | 7.00 | 53.83 | 55.62 | 17.26 | Upgrade
|
| EPS (Diluted) | -5.42 | 23.02 | 7.00 | 53.83 | 55.62 | 17.26 | Upgrade
|
| EPS Growth | - | 228.87% | -87.00% | -3.23% | 222.25% | 25.89% | Upgrade
|
| Free Cash Flow | - | -105.99 | 87.45 | -108.96 | 161.98 | 20.69 | Upgrade
|
| Free Cash Flow Per Share | - | -34.30 | 28.30 | -35.27 | 52.42 | 6.70 | Upgrade
|
| Dividend Per Share | - | 1.000 | 1.000 | 1.000 | 1.000 | - | Upgrade
|
| Gross Margin | 2.80% | 6.71% | 4.02% | 10.58% | 14.40% | 8.33% | Upgrade
|
| Operating Margin | -0.45% | 3.41% | 0.66% | 7.53% | 10.72% | 4.77% | Upgrade
|
| Profit Margin | -0.58% | 2.49% | 0.77% | 5.35% | 7.75% | 2.98% | Upgrade
|
| Free Cash Flow Margin | - | -3.71% | 3.10% | -3.51% | 7.30% | 1.16% | Upgrade
|
| EBITDA | -6.38 | 104.08 | 25.12 | 240.28 | 243.71 | 90.44 | Upgrade
|
| EBITDA Margin | -0.22% | 3.64% | 0.89% | 7.73% | 10.98% | 5.05% | Upgrade
|
| D&A For EBITDA | 6.59 | 6.53 | 6.46 | 6.42 | 5.94 | 4.93 | Upgrade
|
| EBIT | -12.96 | 97.54 | 18.66 | 233.86 | 237.78 | 85.52 | Upgrade
|
| EBIT Margin | -0.45% | 3.41% | 0.66% | 7.53% | 10.72% | 4.77% | Upgrade
|
| Effective Tax Rate | - | 28.06% | 14.19% | 26.19% | 27.19% | 27.38% | Upgrade
|
| Revenue as Reported | 2,902 | 2,868 | 2,830 | 3,111 | 2,224 | 1,795 | Upgrade
|
| Advertising Expenses | - | 3.14 | 1.43 | 1.72 | 0.62 | 0.79 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.